John Crowley, CEO of the Biotechnology Innovation Organization (Credit: BIO via website)
June 11, 2024 09:02 AM EDT
China
In Focus

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

Andrew Dunn

Senior Biopharma Correspondent

Jared Whitlock

Features Editor

Max Bayer

Pharma Reporter

SAN DIEGO — Fac­ing an ex­is­ten­tial mo­ment in how drugs are de­vel­oped and sold, biotech’s key lob­by­ing group has en­trust­ed a new leader, who is wrap­ping …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times